Baxter International Inc
BAX
25.39
0.00
0.00%
Baxter International Inc
US · BAX
#1293 by market cap
Listed 2015
25.39
0.00
0.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:33
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.51% 0.00pp
- Institutions
- 886 -1
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund91.73%
Hedge Fund4.23%
Public Company2.98%
Private Company2.24%
Government Pension Fund1.08%
Sovereign Wealth Fund0.81%
Individual/Insider0.42%
Insurance Company0.17%
Family Office/Trust0.13%
Top holders as of 2026-09-30
BlackRock
12.67% · 65.54M sh
Pzena Investment Management, Inc.
12.07% · 62.43M sh
Dodge & Cox
10.76% · 55.65M sh
Vanguard Capital Management, LLC
7.12% · 36.83M sh
FMR
6.20% · 32.10M sh
Vanguard Portfolio Management, LLC
4.53% · 23.41M sh
State Street Global Advisors
3.99% · 20.62M sh
Strategic Advisers LLC
3.74% · 19.36M sh
Geode Capital Management, LLC
2.69% · 13.93M sh
Greenhaven Associates Inc
2.40% · 12.40M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Jose Almeida | Former Advisor | 0.11% |
| Jeanne Mason | Former Chief Human Resources Officer | 0.04% |
| Heather Knight | Former Executive VP, COO and Interim Group President of Medical Products & Therapies | 0.03% |
| Reazur Rasul | Former Executive VP & Group President of Healthcare Systems and Technologies | 0.02% |
| Christopher Toth | Chief Executive Officer | 0.02% |
| David Rosenbloom | Executive Vice President | 0.02% |
| Maria Soriano | -- | 0.01% |
| Joel Grade | Former Chief Financial Officer | 0.01% |
| David Shafer | Independent Chairperson | 0.01% |
| Andrew Hider | CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | John Rogers | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-14 | Bernie Heine | Interim Chief Accounting Officer & Controller | Initial Statement of Beneficial | 0 | -- |
| 2026-09-01 | Andrew Hider | CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director | Sale to Issuer | -54,276 | $25.70 |
| 2026-09-01 | Julie Foster | President of Front Line Care | Sale to Issuer | -2,098 | $25.70 |
| 2026-08-31 | James Teaff | President of Care & Connectivity Solutions | Sale to Issuer | -750 | $25.48 |
| 2026-06-01 | Steven Wallace | President of Advanced Surgery & Commercial Excellence | Sale to Issuer | -153 | $18.68 |
| 2026-06-01 | James Teaff | President of Care & Connectivity Solutions | Sale to Issuer | -321 | $18.68 |
| 2026-05-31 | Anita Zielinski | Former Interim CFO, Senior VP, Chief Accounting Officer & Controller | Other Acquisition | +13,426 | -- |
| 2026-05-04 | Michael McDonnell | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Amy McBride-Wendell | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Patricia Morrison | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Nancy Schlichting | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | David Shafer | Independent Chairperson | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Jeffrey Craig | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | David Wilkes | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | William Ampofo | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-03-31 | Steven Wallace | President of Advanced Surgery & Commercial Excellence | Initial Statement of Beneficial | 0 | -- |
| 2026-03-31 | Julie Foster | President of Front Line Care | Initial Statement of Beneficial | 0 | -- |
| 2026-03-31 | James Teaff | President of Care & Connectivity Solutions | Initial Statement of Beneficial | 0 | -- |
| 2026-03-05 | Joel Grade | Former Chief Financial Officer | Sale to Issuer | -8,153 | $17.69 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:33:57 · For reference only, not investment advice and not tailored to your situation.
Baxter International Inc discussion 0 comments